BioSpace News Archive

Axsome Therapeutics, Inc. today announced that it has dosed the first patient in the FOCUS Phase 3 trial of solriamfetol, an investigational treatment for attention deficit hyperactivity disorder (ADHD) in adults.

BrainStorm Cell Therapeutics Inc. this week presented new biomarker data from the Phase 3 trial of its late-stage investigational ALS treatment, NurOwn at the 2023 ALS and Related Motor Neuron Diseases Gordon Research Conference.

Can-Fite invites individual and institutional investors as well as analysts to attend its real-time, interactive presentation at the Emerging Growth Conference.

BeiGene today announced that the Company will host an investor Research and Development Day in New York City and via webcast on July 18, 2023.

Castle Biosciences, Inc. will present new data on its gene expression profile (GEP) risk-stratification test for patients with cutaneous squamous cell carcinoma (SCC), DecisionDx®-SCC, and its GEP risk-stratification test for patients with cutaneous melanoma (CM), DecisionDx®-Melanoma, at the American Head & Neck Society’s (AHNS) 11th International Conference.

Bausch Health Companies Inc. (NYSE/TSX:BHC) and KKR today announced that Bausch Receivables Funding LP, an Ontario limited partnership and wholly-owned subsidiary of Bausch Health, has entered into a $600 million non-recourse financing facility with KKR and its credit funds and accounts.

BioRestorative Therapies Inc. (NASDAQ:BRTX) has received a unanimous recommendation to proceed in its Phase 2 clinical trial for chronic lumbar disc disease, BRTX-100.

CytoSorbents Corporation announced that it has completed enrollment of the pivotal Safe and Timely Antithrombotic Removal – Ticagrelor ( STAR-T ) randomized, controlled trial, evaluating the ability of DrugSorb ® -ATR to reduce perioperative bleeding in patients undergoing cardiothoracic surgery on ticagrelor.

AMN Healthcare Services, Inc. (NYSE: AMN), has scheduled a conference call to discuss its second quarter 2023 financial results and third quarter 2023 outlook on Thursday, August 3, 2023, at 5:00 p.m. Eastern Time.

ZyVersa Therapeutics, Inc. announces that the European Patent Office granted a patent covering the company’s Phase 2a-ready Cholesterol Efflux Mediator™ VAR 200 (2-hydroxypropyl-beta-cyclodextrin) for use in diabetic nephropathy/diabetic kidney disease (Patent Number EP 2 836 221).